Locally-confined signet-ring cell carcinoma of the prostate: a case report of a long-term survivor.
It is generally believed that signet-ring cell carcinoma (SRCC) of the prostate is a high-grade neoplasm with a poor prognosis. We report a case of a long-term survivor diagnosed with localized prostatic SRCC (T3N0M0), who has been alive without any clinical evidence of disease for 100 months after combination therapy which consisted of local irradiation and hormone administration. A posttreatment needle biopsy confirmed the pathological complete response.
Yoshimura
K
K
Department of Urology, Cancer Institute, Tokyo, Japan.
Fukui
I
I
Ishikawa
Y
Y
Maeda
H
H
Yamauchi
T
T
Kawai
T
T
D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001707:Biopsy, Needle; D018279:Carcinoma, Signet Ring Cell / Q000097:blood / Q000473:pathology* / Q000628:therapy; D004054:Diethylstilbestrol / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000628:therapy; D018714:Radiotherapy, Adjuvant
D000970:Antineoplastic Agents; D004054:Diethylstilbestrol; C004955:fosfestrol; D017430:Prostate-Specific Antigen